News Related to B-Cell Mediated Autoimmune Disease

Related coverage linked through entity extraction aliases.

iPSC-Derived NK Cell Therapies Gain Momentum with Regulatory Approvals and Expanding Clinical Pipeline

Jun 04, 2026

iPSC-derived NK cell therapies are advancing rapidly with 12+ companies developing 15+ pipeline drugs. Japan's PMDA approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025. Key clinical milestones include Century Therapeutics' CNTY-101 continuing in a Phase I/II trial.

Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases

Feb 15, 2026

DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.